Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
Ace Joseph Hatch
No relevant relationships to disclose
Herbert Pang
No relevant relationships to disclose
Mark D. Starr
No relevant relationships to disclose
John C. Brady
No relevant relationships to disclose
Jingquan Jia
No relevant relationships to disclose
Chen Jiang
No relevant relationships to disclose
Alexander Sibley
No relevant relationships to disclose
Kouros Owzar
No relevant relationships to disclose
Donna Niedzwiecki
No relevant relationships to disclose
Alan P. Venook
Consultant or Advisory Role - Bristol-Myers Squibb (U); Roche/Genentech (U)
Research Funding - Bristol-Myers Squibb; Roche/Genentech
Stephanie M. Cushman
No relevant relationships to disclose
Herbert Hurwitz
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Regeneron; Roche; Sanofi
Research Funding - Amgen; Genentech; GlaxoSmithKline; Morphotek; Roche; Sanofi ; TRACON Pharma
Andrew B. Nixon
Consultant or Advisory Role - GlaxoSmithKline; Novartis
Research Funding - Amgen; Pfizer; Roche; TRACON Pharma